新辅助化疗剂量强度与HER2阴性早期乳腺癌病理完全缓解及无事件生存的关联
该回顾性研究分析了两家意大利中心365例接受新辅助化疗的HER2阴性早期乳腺癌患者,按85%阈值分类及连续评估相对剂量强度(RDI)。三阴性队列中高RDI与病理完全缓解率提高显著相关(分类OR 3.15,p<0.001;连续OR 1.05,p<0.001),高RDI与无事件生存改善在单因素分析中相关但多因素调整后未保留;激素受体阳性队列中高RDI与无事件生存改善显著相关(分类HR 0.29,p=0.006;连续HR 0.96,p=0.004),但与病理完全缓解无关。
要点
- 三阴性早期乳腺癌中高RDI与病理完全缓解率提高显著相关。
- 激素受体阳性队列中高RDI与无事件生存改善显著相关。
- 三阴性队列高RDI与无事件生存的关联在多因素调整后未保留。
核心结论
- 高相对剂量强度与接受新辅助化疗的HER2阴性早期乳腺癌患者临床结局改善相关。
- 在治愈性治疗中维持最佳相对剂量强度对最大化疗效至关重要。
研究设计与样本
- 回顾性分析两家意大利中心接受新辅助化疗的HER2阴性早期乳腺癌患者数据。
- 共纳入365例患者,其中三阴性218例,激素受体阳性147例。
- 相对剂量强度按85%阈值分类评估及连续评估,采用回归分析关联病理完全缓解和无事件生存。
主要发现
- 三阴性队列中63.3%患者接受高相对剂量强度。
- 三阴性队列高相对剂量强度与病理完全缓解率提高显著相关(分类OR 3.15,p<0.001;连续OR 1.05,p<0.001)。
- 三阴性队列高相对剂量强度与无事件生存改善在单因素分析中相关(分类HR 0.48,p=0.010;连续HR 0.98,p=0.011),但多因素调整病理完全缓解、年龄、分期和剂量密集化疗后未保留。
- 激素受体阳性队列中88.4%患者接受高相对剂量强度,未观察到相对剂量强度与病理完全缓解的关联。
- 激素受体阳性队列高相对剂量强度与无事件生存改善显著相关(分类HR 0.29,p=0.006;连续HR 0.96,p=0.004),调整年龄、分期和治疗方案。
关键数值与推荐
- 相对剂量强度分类阈值采用85%。
- 三阴性队列病理完全缓解关联:分类OR 3.15(p<0.001),连续OR 1.05(p<0.001)。
- 三阴性队列无事件生存单因素关联:分类HR 0.48(p=0.010),连续HR 0.98(p=0.011)。
- 激素受体阳性队列无事件生存关联:分类HR 0.29(p=0.006),连续HR 0.96(p=0.004)。
临床怎么用
- 在接受新辅助化疗的HER2阴性早期乳腺癌患者中,应关注并维持最佳相对剂量强度以最大化治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In early-stage breast cancer (eBC), the efficacy of neoadjuvant chemotherapy (NACT) may be compromised by dose delays or reductions. A reduced relative dose intensity (RDI, i.e. the ratio of the delivered to planned chemotherapy dose), can lead to diminished clinical outcomes, but real-world data are limited in this setting. METHODS: We retrospectively analyzed data from HER2-negative eBC patients who received NACT at two Italian centers. RDI was assessed categorically with a 85 % threshold and continuously. We assessed the association between RDI and pathological complete response (pCR) and event-free survival (EFS) using regression analysis. RESULTS: 365 patients were included, comprising 218 triple-negative (TN) and 147 hormone receptor-positive (HR+) cases. In the TN cohort, 63.3 % of patients received a high RDI. High RDI was significantly associated with increased pCR rates in univariate and multivariate analyses (categorical RDI: OR 3.15, p < 0.001; continuous RDI: OR 1.05, p < 0.001). High RDI was associated with improved EFS in univariate analysis (categorical RDI: HR 0.48, p = 0.010; continuous RDI: HR 0.98, p = 0.011); however, this association was not retained in multivariate model adjusted for pCR, age, stage, and dose-dense chemotherapy. In the HR+ cohort, where 88.4 % of patients received a high RDI, no association was observed between RDI and pCR. Nevertheless, high RDI was significantly associated with improved EFS in univariate and multivariate models (categorical RDI: HR 0.29, p = 0.006; continuous RDI: HR 0.96, p = 0.004) adjusted for age, stage, and treatment schedule. CONCLUSION: High RDI is associated with improved clinical outcomes in patients with HER2-negative eBC undergoing NACT. Maintaining an optimal RDI is crucial to maximize treatment efficacy in the curative setting.
引用
- Buonaiuto R, Martorana F, Marino P, et al. Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer. Eur J Cancer. 2025. PMID: 41259941. doi:10.1016/j.ejca.2025.116102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。